These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30868419)

  • 1. Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification.
    Toyos MM
    Ophthalmol Ther; 2019 Jun; 8(2):261-270. PubMed ID: 30868419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromfenac Ophthalmic Solution 0.07% Versus Nepafenac Ophthalmic Suspension 0.3% for Post-Cataract Surgery Inflammation: A Pilot Study of Identical Dosing Regimens with Pre-Surgical "Pulse" Dose.
    Silverstein SM
    Ophthalmol Ther; 2019 Dec; 8(4):577-587. PubMed ID: 31552543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of bromfenac 0.09% QD to nepafenac 0.1% TID after cataract surgery: pilot evaluation of visual acuity, macular volume, and retinal thickness at a single site.
    Cable M
    Clin Ophthalmol; 2012; 6():997-1004. PubMed ID: 22815642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials.
    Walters TR; Goldberg DF; Peace JH; Gow JA;
    Ophthalmology; 2014 Jan; 121(1):25-33. PubMed ID: 24021896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies.
    Singh RP; Lehmann R; Martel J; Jong K; Pollack A; Tsorbatzoglou A; Staurenghi G; Cervantes-Coste Cervantes G; Alpern L; Modi S; Svoboda L; Adewale A; Jaffe GJ
    Ophthalmology; 2017 Jun; 124(6):776-785. PubMed ID: 28268098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in patients having phacoemulsification.
    Sahu S; Ram J; Bansal R; Pandav SS; Gupta A
    J Cataract Refract Surg; 2015 Oct; 41(10):2043-8. PubMed ID: 26703278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain.
    Henderson BA; Gayton JL; Chandler SP; Gow JA; Klier SM; McNamara TR;
    Ophthalmology; 2011 Nov; 118(11):2120-7. PubMed ID: 21762992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery.
    Silverstein SM; Jackson MA; Goldberg DF; Muñoz M
    Clin Ophthalmol; 2014; 8():965-72. PubMed ID: 24876763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Efficacy of Dexamethasone, Nepafenac, and Bromfenac for Preventing Pseudophakic Cystoid Macular Edema: an Open-label, Prospective, Randomized Controlled Trial.
    Campa C; Salsini G; Perri P
    Curr Eye Res; 2018 Mar; 43(3):362-367. PubMed ID: 29120255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromfenac 0.09% bioavailability in aqueous humor, prophylactic effect on cystoid macular edema, and clinical signs of ocular inflammation after phacoemulsification in a Mexican population.
    Palacio C; Fernández De Ortega L; Bustos FR; Chávez E; Oregon-Miranda AA; Mercado-Sesma AR
    Clin Ophthalmol; 2016; 10():233-7. PubMed ID: 26869758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anterior Chamber Inflammation After Cataract Surgery: A Randomized Clinical Trial Comparing Bromfenac 0.09% to Dexamethasone 0.1.
    Coassin M; De Maria M; Mastrofilippo V; Braglia L; Cimino L; Sartori A; Fontana L
    Adv Ther; 2019 Oct; 36(10):2712-2722. PubMed ID: 31482510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain.
    Silverstein SM; Cable MG; Sadri E; Peace JH; Fong R; Chandler SP; Gow JA; Klier SM; McNamara TR;
    Curr Med Res Opin; 2011 Sep; 27(9):1693-703. PubMed ID: 21751945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema.
    Mathys KC; Cohen KL
    Eye (Lond); 2010 Jan; 24(1):90-6. PubMed ID: 19229275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy.
    Singh R; Alpern L; Jaffe GJ; Lehmann RP; Lim J; Reiser HJ; Sall K; Walters T; Sager D
    Clin Ophthalmol; 2012; 6():1259-69. PubMed ID: 22927737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Effect of Diclofenac 0.1% and Nepafenac 0.1% on Aqueous Flare in Patients Undergoing Cataract Surgery: A Prospective Randomized Study.
    Cagini C; Pellegrino A; Cerquaglia A; Iaccheri B; Lupidi M; Fiore T
    Curr Eye Res; 2020 Sep; 45(9):1089-1093. PubMed ID: 32004437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of the efficacy and safety of bromfenac, nepafenac and diclofenac sodium for the prevention of cystoid macular edema after phacoemulsification.
    Chinchurreta Capote AM; Lorenzo Soto M; Rivas Ruiz F; Caso Peláez E; García Vazquez A; ; Ramos Suárez A
    Int J Ophthalmol; 2018; 11(7):1210-1216. PubMed ID: 30046541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.
    Donnenfeld ED; Holland EJ; Stewart RH; Gow JA; Grillone LR;
    Ophthalmology; 2007 Sep; 114(9):1653-62. PubMed ID: 17445902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy.
    Pollack A; Staurenghi G; Sager D; Mukesh B; Reiser H; Singh RP
    Br J Ophthalmol; 2017 Apr; 101(4):423-427. PubMed ID: 27388251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification.
    Bucci FA; Waterbury LD
    Adv Ther; 2011 Dec; 28(12):1089-95. PubMed ID: 22105509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK).
    Durrie DS; Kennard MG; Boghossian AJ
    Adv Ther; 2007; 24(6):1278-85. PubMed ID: 18165210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.